The pharmaceutical sector has reappeared in the rising tide, and one stock has risen and stopped 25 times in the past year

【Pharmaceutical Network Pharmaceutical Stock Market】On September 30, the pharmaceutical sector reappeared to rise and stop, Longjin Pharmaceutical, Luoxin Pharmaceutical, Huasen Pharmaceutical, Lisheng Pharmaceutical, Xinhua Pharmaceutical and other stocks rose and stopped rapidly, and Enwei Pharmaceutical, Hongri Pharmaceutical, China Resources Shuanghe and so on followed suit
.
Among them, Longjin Pharmaceutical rose and stopped in the intraday today, at 9.
93 yuan, and the current sealed single 287397 hand, equivalent to 285 million yuan
.
Up to now, the transaction is 44.
8178 million yuan, and the turnover rate is 1.
19%.
From the perspective of the reasons for the change of the stock, there are mainly the following three aspects: First, the company is a pharmaceutical company engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs
.
The company's main products are Longjin injection of calendulain, is a high-purity Chinese medicine lyophilized powder injection, the product has the effect of activating blood stasis, through the network and analgesia, used for the treatment of cardiovascular and cerebrovascular diseases, mainly used for the treatment of stroke and its sequelae, coronary heart disease, angina
.
Second, the company's leading product Longjin injection of calendulin is a single component of the preparation of lantern acetylene, its purity of more than 98%, can be measured according to the chemical standards, is a typical case of the combination of traditional Chinese medicine and western medicine methods and theories that have been discussed in China
.
As a Chinese medicine injection, calendulin for injection not only conforms to the theory of traditional Chinese medicine, but also can use modern Western medicine theory to explain its good clinical efficacy and low adverse reaction rate
.
Third, in February 2019, the company increased the capital of Yunnan Muya Agricultural Technology Co.
, Ltd.
(Muya Agriculture) by 15 million yuan and acquired 51% of its equity
.
Muya Agriculture's main business is the large-scale cultivation of industrial hemp
.
It is worth mentioning that Longjin Pharmaceutical has accumulated 25 times
in the past year.
The 2021 annual report shows that the company achieved operating income of 702 million yuan, an increase of 176.
55% year-on-year; The net profit attributable to the shareholders of the listed company was 3.
0934 million yuan, down 73.
81%
year-on-year.
According to the 2022 interim report, the company achieved a main revenue of 78.
1111 million yuan, down 80.
35% year-on-year; Net profit attributable to the mother - 2.
4668 million yuan, down 150.
62% year-on-year; Excluding non-net profit - 8.
6928 million yuan, down 1667.
81%
year-on-year.
Longjin Pharmaceutical belongs to the traditional Chinese medicine sector, today the entire Chinese medicine sector rose sharply, in addition to Longjin Pharmaceutical, there are Huasen Pharmaceutical intraday up and down, quoted at 12.
32 yuan, the current seal 122573 hand, equivalent to 151 million yuan
.
As of now, the transaction is 11.
9664 million yuan, and the turnover rate is 0.
36%.

In addition, Enwei Pharmaceutical, Fangsheng Pharmaceutical, Dali Pharmaceutical, Jingjing Pharmaceutical, Zixin Pharmaceutical and many other traditional Chinese medicine stocks have also followed suit, and the entire sector has performed relatively actively
.
On the news side, the Chinese medicine industry is supported by favorable policies, and on September 21, the relevant departments issued a notice to promote the development of special activities for the promotion of traditional Chinese medicine health, which mainly includes 8 contents
, such as traditional Chinese medicine health promotion activities for the elderly and traditional Chinese medicine prevention activities for chronic diseases.
In the next 3 years, China will carry out special activities for the promotion of traditional Chinese medicine health in the Healthy China Action, and it is expected that by 2025, the health management rate of traditional Chinese medicine for the elderly over 65 years old will reach 75%, aiming to integrate the concept of traditional Chinese medicine into the whole process of health promotion, the whole process of major disease prevention and treatment, and the whole process of
disease diagnosis and treatment.
Founder Securities believes that the recent policy has further strengthened the promotion of the Chinese medicine industry, and with the significant enhancement of the health service capacity of traditional Chinese medicine, the demand for traditional Chinese medicine will be further improved, which is good for the traditional Chinese medicine sector
.
Zheshang Securities also pointed out that the state attaches great importance to the innovative development of traditional Chinese medicine and the intervention of traditional Chinese medicine to treat diseases, the prevention and treatment of traditional Chinese medicine diseases and health management has become an inevitable development trend, and the traditional Chinese medicine industry has ushered in a new round of development opportunities
under the frequent emergence of favorable policies.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.